Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | Director | May 07, 2026 | May 11, 2026 |
| TUPPERWARE BRANDS CORPTUP · Entity 90566 | Director | May 06, 2022 | May 10, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEXX LABORATORIES INC /DE
Report date May 07, 2026 · Filed May 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 519 |
Reported balance
After 2026-05-07 transaction · row 1
1 source rowRow 1 · 2026-05-07 · Exercise / conversion · Acquired 257 · Balance 519 |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-07 · Exercise / conversion · Disposed 257 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock that vested in one installment on May 7, 2026. F4: Not applicable. |
| Common StockSEC Table I · non-derivative | IndirectTrust of M. Anne Szostak | 1,542 |
Reported balance
Holding disclosure · report date 2026-05-07 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,542 F1: The reporting person is the settlor of the Trust of M. Anne Szostak ("Trust") and the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares held by the Trust. |
| Common StockSEC Table I · non-derivative | IndirectThe O'Hanian-Szostak Family Foundation | 259 |
Reported balance
Holding disclosure · report date 2026-05-07 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 259 F2: The reporting person is a trustee of The O'Hanian-Szostak Family Foundation ('Foundation') and has power to direct the distribution of assets held by the Foundation. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is the settlor of the Trust of M. Anne Szostak ("Trust") and the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares held by the Trust.
F2: The reporting person is a trustee of The O'Hanian-Szostak Family Foundation ('Foundation') and has power to direct the distribution of assets held by the Foundation.
F3: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock that vested in one installment on May 7, 2026.
F4: Not applicable.
TUPPERWARE BRANDS CORP
Report date May 06, 2022 · Filed May 10, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 88,858 |
Reported balance
After 2022-05-06 transaction · row 1
1 source rowRow 1 · 2022-05-06 · Grant · Acquired 15,106 · Balance 88,858 F1: Restricted Stock Unit award that vests on the Issuer's next Annual Meeting of Shareholders, currently planned for May 5, 2023, at which time the units convert into Tupperware Brands' Corporation common stock on a one-for-one basis. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Unit award that vests on the Issuer's next Annual Meeting of Shareholders, currently planned for May 5, 2023, at which time the units convert into Tupperware Brands' Corporation common stock on a one-for-one basis.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Keurig Dr Pepper Inc.
Report date July 09, 2018 · Filed July 10, 2018
Section 16 reporting ended · disclosed 2018-07-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,095 |
Ending reported balance
After 2018-07-09 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2018-07-09 · Exercise / conversion · Acquired 1,685 · Balance 1,685 F1: Pursuant to the Agreement and Plan of Merger, dated as of January 29, 2018, (the "Merger Agreement"), by and among Maple Parent Holdings Corp., a Delaware corporation ("Maple Parent"), DPS and Salt Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of DPS ("Merger Sub"), Merger Sub merged on July 9, 2018 with and into Maple Parent (the "Merger"), with Maple Parent surviving the Merger as a wholly-owned subsidiary of DPS. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Restricted Stock Unit ("RSU") of DPS will be settled in exchange for (i) a number of shares underlying such DPS RSU, and (ii) an amount in cash equal to the number of shares underlying such DPS RSU multiplied by the special cash dividend per share amount. Row 2 · 2018-07-09 · Other · Acquired 91 · Balance 1,776 F2: These shares are restricted stock units acquired with dividend equivalent payments made under the Issuer's dividend reinvestment plan with respect to the shares referenced in row (1) above. Row 3 · 2018-07-09 · Exercise / conversion · Acquired 1,796 · Balance 3,572 F1: Pursuant to the Agreement and Plan of Merger, dated as of January 29, 2018, (the "Merger Agreement"), by and among Maple Parent Holdings Corp., a Delaware corporation ("Maple Parent"), DPS and Salt Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of DPS ("Merger Sub"), Merger Sub merged on July 9, 2018 with and into Maple Parent (the "Merger"), with Maple Parent surviving the Merger as a wholly-owned subsidiary of DPS. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Restricted Stock Unit ("RSU") of DPS will be settled in exchange for (i) a number of shares underlying such DPS RSU, and (ii) an amount in cash equal to the number of shares underlying such DPS RSU multiplied by the special cash dividend per share amount. Row 4 · 2018-07-09 · Other · Acquired 54 · Balance 3,626 F3: These shares are restricted stock units acquired with dividend equivalent payments made under the Issuer's dividend reinvestment plan with respect to the shares referenced in row (3) above. Row 5 · 2018-07-09 · Exercise / conversion · Acquired 1,462 · Balance 5,088 F1: Pursuant to the Agreement and Plan of Merger, dated as of January 29, 2018, (the "Merger Agreement"), by and among Maple Parent Holdings Corp., a Delaware corporation ("Maple Parent"), DPS and Salt Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of DPS ("Merger Sub"), Merger Sub merged on July 9, 2018 with and into Maple Parent (the "Merger"), with Maple Parent surviving the Merger as a wholly-owned subsidiary of DPS. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Restricted Stock Unit ("RSU") of DPS will be settled in exchange for (i) a number of shares underlying such DPS RSU, and (ii) an amount in cash equal to the number of shares underlying such DPS RSU multiplied by the special cash dividend per share amount. Row 6 · 2018-07-09 · Other · Acquired 7 · Balance 5,095 F4: These shares are restricted stock units acquired with dividend equivalent payments made under the Issuer's dividend reinvestment plan with respect to the shares referenced in row (5) above. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-07-09 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-07-09 · Exercise / conversion · Disposed 1,685 · Balance 0 F5: Each restricted stock unit represented a contingent right to receive one share of the Issuer's Common Stock and was granted pursuant to the Issuer's Omnibus Stock Incentive Plan of 2009. F6: Pursuant to the Merger Agreement, immediately prior to the effective time, each outstanding RSU vested and was settled in exchange for (i) a number of shares of DPS common stock equal to the number of shares underlying such DPS RSU, and (ii) an amount in cash equal to the number of shares underlying such DPS RSU multiplied by the special cash dividend per share amount. F7: These restricted stock units were to vest on March 2, 2019. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-07-09 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-07-09 · Exercise / conversion · Disposed 1,796 · Balance 0 F5: Each restricted stock unit represented a contingent right to receive one share of the Issuer's Common Stock and was granted pursuant to the Issuer's Omnibus Stock Incentive Plan of 2009. F6: Pursuant to the Merger Agreement, immediately prior to the effective time, each outstanding RSU vested and was settled in exchange for (i) a number of shares of DPS common stock equal to the number of shares underlying such DPS RSU, and (ii) an amount in cash equal to the number of shares underlying such DPS RSU multiplied by the special cash dividend per share amount. F8: These restricted stock units were to vest on March 4, 2020. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-07-09 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-07-09 · Exercise / conversion · Disposed 1,462 · Balance 0 F5: Each restricted stock unit represented a contingent right to receive one share of the Issuer's Common Stock and was granted pursuant to the Issuer's Omnibus Stock Incentive Plan of 2009. F6: Pursuant to the Merger Agreement, immediately prior to the effective time, each outstanding RSU vested and was settled in exchange for (i) a number of shares of DPS common stock equal to the number of shares underlying such DPS RSU, and (ii) an amount in cash equal to the number of shares underlying such DPS RSU multiplied by the special cash dividend per share amount. F9: These restricted stock units were to vest on March 4, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of January 29, 2018, (the "Merger Agreement"), by and among Maple Parent Holdings Corp., a Delaware corporation ("Maple Parent"), DPS and Salt Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of DPS ("Merger Sub"), Merger Sub merged on July 9, 2018 with and into Maple Parent (the "Merger"), with Maple Parent surviving the Merger as a wholly-owned subsidiary of DPS. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Restricted Stock Unit ("RSU") of DPS will be settled in exchange for (i) a number of shares underlying such DPS RSU, and (ii) an amount in cash equal to the number of shares underlying such DPS RSU multiplied by the special cash dividend per share amount.
F2: These shares are restricted stock units acquired with dividend equivalent payments made under the Issuer's dividend reinvestment plan with respect to the shares referenced in row (1) above.
F3: These shares are restricted stock units acquired with dividend equivalent payments made under the Issuer's dividend reinvestment plan with respect to the shares referenced in row (3) above.
F4: These shares are restricted stock units acquired with dividend equivalent payments made under the Issuer's dividend reinvestment plan with respect to the shares referenced in row (5) above.
F5: Each restricted stock unit represented a contingent right to receive one share of the Issuer's Common Stock and was granted pursuant to the Issuer's Omnibus Stock Incentive Plan of 2009.
F6: Pursuant to the Merger Agreement, immediately prior to the effective time, each outstanding RSU vested and was settled in exchange for (i) a number of shares of DPS common stock equal to the number of shares underlying such DPS RSU, and (ii) an amount in cash equal to the number of shares underlying such DPS RSU multiplied by the special cash dividend per share amount.
F7: These restricted stock units were to vest on March 2, 2019.
F8: These restricted stock units were to vest on March 4, 2020.
F9: These restricted stock units were to vest on March 4, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 06, 2021 Filed Aug 9, 2021 21:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 300 | $689.60 | $206,881.20 |
DisclosureSEC source: 0001567619-21-014772 · doc1.xml · nonDerivative · entry 6 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 2021 Szostak IDEXX GRAT Disclosed balance after: 8,417 F7 · price: Represents the weighted average price of the shares sold ranging from a low of $689.27 to a high of $690.23 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 06, 2021 Filed Aug 9, 2021 21:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 261 | $685.98 | $179,041.93 |
DisclosureSEC source: 0001567619-21-014772 · doc1.xml · nonDerivative · entry 5 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 2021 Szostak IDEXX GRAT Disclosed balance after: 8,717 F6 · price: Represents the weighted average price of the shares sold ranging from a low of $685.48 to a high of $686.35 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 06, 2021 Filed Aug 9, 2021 21:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 439 | $684.96 | $300,696.39 |
DisclosureSEC source: 0001567619-21-014772 · doc1.xml · nonDerivative · entry 4 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 2021 Szostak IDEXX GRAT Disclosed balance after: 8,978 F5 · price: Represents the weighted average price of the shares sold ranging from a low of $684.39 to a high of $685.25 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 06, 2021 Filed Aug 9, 2021 21:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 120 | $683.71 | $82,045.00 |
DisclosureSEC source: 0001567619-21-014772 · doc1.xml · nonDerivative · entry 3 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 2021 Szostak IDEXX GRAT Disclosed balance after: 9,417 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $683.38 to a high of $683.79 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 06, 2021 Filed Aug 9, 2021 21:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 368 | $682.77 | $251,259.51 |
DisclosureSEC source: 0001567619-21-014772 · doc1.xml · nonDerivative · entry 2 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 2021 Szostak IDEXX GRAT Disclosed balance after: 9,537 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $682.30 to a high of $683.20 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 06, 2021 Filed Aug 9, 2021 21:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 312 | $681.49 | $212,624.94 |
DisclosureSEC source: 0001567619-21-014772 · doc1.xml · nonDerivative · entry 1 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 2021 Szostak IDEXX GRAT Disclosed balance after: 9,905 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $681.18 to a high of $682.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F1 · ownership.nature: The reporting person is the settlor and trustee of the 2021 Szostak IDEXX GRAT (the "GRAT"). The GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein. Read SEC document |
| May 12, 2021 Filed May 14, 2021 22:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 723 | Not disclosed Strike: $512.31 | Not disclosed |
DisclosureSEC source: 0001567619-21-010257 · doc1.xml · derivative · entry 2 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 723 Underlying: Common Stock · 723 shares Expires 2031-05-11 F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier. Read SEC document |
| May 12, 2021 Filed May 14, 2021 22:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 224 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-010257 · doc1.xml · derivative · entry 1 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224 Underlying: Common Stock · 224 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier, and are payable as common stock on the vesting date. F3 · price: Not applicable. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier, and are payable as common stock on the vesting date. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier, and are payable as common stock on the vesting date. Read SEC document |
| May 04, 2021 Filed May 6, 2021 15:28 UTC | TUPPERWARE BRANDS CORP TUP · Entity 90566 | GrantCommon Stock | 7,236 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-015703 · form4.xml · nonDerivative · entry 1 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,752 F1 · shares: Restricted Stock Unit award that vests on the Issuer's next Annual Meeting of Shareholders, currently planned for May 6, 2022, at which time the units convert into Tupperware Brands Corporation common stock on a one-for-one basis. On May 4, 2021, the Compensation and Human Capital Committee (the "Committee") of the Issuer's Board of Directors approved equity awards to non-employee directors that are tied to service on the Board during the May 2021 to May 2022 term, as compared to service on the Board during the calendar year (as prior annual non-employee director equity grants had been structured). As a result of this change in approach, the Committee approved a one-time "true-up" payment of Restricted Stock Units that is in addition to the annual grant of $130,000 in value of Restricted Stock Units that each non-employee director receives. Read SEC document |
| February 05, 2021 Filed Feb 8, 2021 23:05 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 10,217 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-002490 · doc1.xml · nonDerivative · entry 13 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 2021 Szostak IDEXX GRAT Disclosed balance after: 10,217 F7 · ownership.nature: The reporting person is the settlor and trustee of the 2021 Szostak IDEXX GRAT (the "GRAT"). The GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein. Read SEC document |
| February 05, 2021 Filed Feb 8, 2021 23:05 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 10,217 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-002490 · doc1.xml · nonDerivative · entry 11 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust of M. Anne Szostak Disclosed balance after: 10,217 Read SEC document |
| February 05, 2021 Filed Feb 8, 2021 23:05 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 10,217 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-002490 · doc1.xml · nonDerivative · entry 10 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 2020 Szostak IDEXX GRAT Disclosed balance after: 0 Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 23:05 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 5,902 | Not disclosed Strike: $85.00 | Not disclosed |
DisclosureSEC source: 0001567619-21-002490 · doc1.xml · derivative · entry 15 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,902 shares Expires 2026-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · price: Not applicable. F9 · derivative.exercise_date: Grant of option to buy 5,902 shares of IDEXX Laboratories, Inc. common stock that became exercisable in one installment on May 4, 2016. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 23:05 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 5,974 | Not disclosed Strike: $64.69 | Not disclosed |
DisclosureSEC source: 0001567619-21-002490 · doc1.xml · derivative · entry 14 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,974 shares Expires 2024-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · price: Not applicable. F8 · derivative.exercise_date: Grant of option to buy 2,987 shares of IDEXX Laboratories, Inc. common stock that became exercisable in one installment on May 7, 2015 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 23:05 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 10,217 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-002490 · doc1.xml · nonDerivative · entry 12 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust of M. Anne Szostak Disclosed balance after: 0 Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 23:05 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 300 | $492.39 | $147,718.38 |
DisclosureSEC source: 0001567619-21-002490 · doc1.xml · nonDerivative · entry 9 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust of M. Anne Szostak Disclosed balance after: 0 F6 · price: Represents the weighted average price of the shares sold ranging from a low of $492.31 to a high of $492.46 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 23:05 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,100 | $491.56 | $540,716.44 |
DisclosureSEC source: 0001567619-21-002490 · doc1.xml · nonDerivative · entry 8 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust of M. Anne Szostak Disclosed balance after: 300 F5 · price: Represents the weighted average price of the shares sold ranging from a low of $491.05 to a high of $492.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 23:05 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,399 | $490.70 | $1,667,878.76 |
DisclosureSEC source: 0001567619-21-002490 · doc1.xml · nonDerivative · entry 7 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust of M. Anne Szostak Disclosed balance after: 1,400 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $490.02 to a high of $491.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 23:05 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 4,286 | $489.23 | $2,096,836.35 |
DisclosureSEC source: 0001567619-21-002490 · doc1.xml · nonDerivative · entry 6 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust of M. Anne Szostak Disclosed balance after: 4,799 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $489.01 to a high of $490.01 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 23:05 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,791 | $488.24 | $1,362,665.84 |
DisclosureSEC source: 0001567619-21-002490 · doc1.xml · nonDerivative · entry 5 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust of M. Anne Szostak Disclosed balance after: 9,085 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $488.00 to a high of $489.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 23:05 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 11,876 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-002490 · doc1.xml · nonDerivative · entry 4 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust of M. Anne Szostak Disclosed balance after: 11,876 F1 · ownership.nature: The reporting person is the settlor of the Trust of M. Anne Szostak ("Trust") and the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares transferred to the Trust. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 23:05 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 11,876 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-002490 · doc1.xml · nonDerivative · entry 3 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 23:05 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 5,902 | $85.00 | $501,670.00 |
DisclosureSEC source: 0001567619-21-002490 · doc1.xml · nonDerivative · entry 2 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 23:05 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 5,974 | $64.69 | $386,458.06 |
DisclosureSEC source: 0001567619-21-002490 · doc1.xml · nonDerivative · entry 1 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2020 Filed Nov 10, 2020 18:03 UTC | TUPPERWARE BRANDS CORP TUP · Entity 90566 | GiftCommon Stock | 3,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-028670 · form4.xml · nonDerivative · entry 2 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,368 Read SEC document |
| November 10, 2020 Filed Nov 10, 2020 18:03 UTC | TUPPERWARE BRANDS CORP TUP · Entity 90566 | SaleCommon Stock | 1,000 | $28.43 | $28,430.00 |
DisclosureSEC source: 0001127602-20-028670 · form4.xml · nonDerivative · entry 1 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,408 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.38 to $28.48, inclusive. The reporting person undertakes to provide to Tupperware Brands Corporation, any security holder of Tupperware Brands Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price withing the range set forth in footnote (1) to this Form 4. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 7,722 | Not disclosed Strike: $63.95 | Not disclosed |
DisclosureSEC source: 0001567619-20-011544 · doc1.xml · derivative · entry 8 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,722 shares Expires 2025-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: Not applicable. F6 · derivative.exercise_date: Grant of option to buy 3,861 shares of IDEXX Laboratories, Inc. common stock that became exercisable in one annual installment on May 6, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,690 | $308.08 | $520,657.57 |
DisclosureSEC source: 0001567619-20-011544 · doc1.xml · nonDerivative · entry 6 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · M. Anne Szostak Trust Disclosed balance after: 0 F5 · price: Represents the weighted average price of the shares sold ranging from a low of $307.72 to a high of $308.49 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F1 · ownership.nature: The reporting person is the settlor of the M. Anne Szostak Trust ("Trust"), the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares transferred to the Trust. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,052 | $307.02 | $937,028.09 |
DisclosureSEC source: 0001567619-20-011544 · doc1.xml · nonDerivative · entry 5 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · M. Anne Szostak Trust Disclosed balance after: 1,690 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $306.67 to a high of $307.40 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F1 · ownership.nature: The reporting person is the settlor of the M. Anne Szostak Trust ("Trust"), the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares transferred to the Trust. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,980 | $306.12 | $912,234.92 |
DisclosureSEC source: 0001567619-20-011544 · doc1.xml · nonDerivative · entry 4 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · M. Anne Szostak Trust Disclosed balance after: 4,742 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $305.53 to a high of $306.52 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F1 · ownership.nature: The reporting person is the settlor of the M. Anne Szostak Trust ("Trust"), the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares transferred to the Trust. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 7,722 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-011544 · doc1.xml · nonDerivative · entry 3 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · M. Anne Szostak Trust Disclosed balance after: 7,722 F1 · ownership.nature: The reporting person is the settlor of the M. Anne Szostak Trust ("Trust"), the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares transferred to the Trust. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 7,722 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-011544 · doc1.xml · nonDerivative · entry 2 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 21:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 7,722 | $63.95 | $493,821.90 |
DisclosureSEC source: 0001567619-20-011544 · doc1.xml · nonDerivative · entry 1 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,722 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2020 Filed May 22, 2020 16:55 UTC | TUPPERWARE BRANDS CORP TUP · Entity 90566 | GrantCommon Stock | 32,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-017810 · form4.xml · nonDerivative · entry 1 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,408 F1 · shares: Restricted Stock Unit award that vests on the Issuer's next Annual Meeting of Shareholders, currently planned for May 19, 2021, at which time the units convert into Tupperware Brands' Corporation common stock on a one-for-one basis. Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 1,279 | Not disclosed Strike: $283.59 | Not disclosed |
DisclosureSEC source: 0001567619-20-009379 · doc1.xml · derivative · entry 7 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,279 Underlying: Common Stock · 1,279 shares Expires 2030-05-05 F5 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier. Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantDeferred Stock Unit · Derivative | 370 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-009379 · doc1.xml · derivative · entry 6 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,515 Underlying: Common Stock · 370 shares Expires not disclosed F3 · derivative.exercise_price: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F5 · price: Not applicable. F3 · derivative.exercise_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F3 · derivative.expiration_date: Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2021 annual meeting of shareholders, whichever event is earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 10,217 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-009379 · doc1.xml · nonDerivative · entry 5 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 2020 Szostak IDEXX GRAT Disclosed balance after: 10,217 F2 · ownership.nature: The reporting person is the settlor and trustee of the 2020 Szostak IDEXX GRAT (the "GRAT"). The GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein. Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 10,217 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-009379 · doc1.xml · nonDerivative · entry 4 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · M. Anne Szostak Trust Disclosed balance after: 0 Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 7,301 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-009379 · doc1.xml · nonDerivative · entry 3 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · M. Anne Szostak Trust Disclosed balance after: 10,217 F1 · ownership.nature: The reporting person is the settlor of the M. Anne Szostak Trust ("Trust"), the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares transferred to the Trust. Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 584 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-009379 · doc1.xml · nonDerivative · entry 2 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| May 06, 2020 Filed May 8, 2020 21:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 6,717 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-009379 · doc1.xml · nonDerivative · entry 1 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 2018 Szostak IDEXX GRAT Disclosed balance after: 0 Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 22:27 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 8,790 | Not disclosed Strike: $43.68 | Not disclosed |
DisclosureSEC source: 0001567619-20-004493 · doc1.xml · derivative · entry 7 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,790 shares Expires 2023-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy 4,395 shares of IDEXX Laboratories, Inc. common stock that became exercisable in one annual installment on May 8, 2014 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 22:27 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,200 | $286.98 | $344,378.40 |
DisclosureSEC source: 0001567619-20-004493 · doc1.xml · nonDerivative · entry 5 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · M. Anne Szostak Trust Disclosed balance after: 2,916 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $286.77 to a high of $287.49 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 22:27 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 7,590 | $286.18 | $2,172,091.02 |
DisclosureSEC source: 0001567619-20-004493 · doc1.xml · nonDerivative · entry 4 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · M. Anne Szostak Trust Disclosed balance after: 4,116 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $285.76 to a high of $286.69 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 22:27 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 8,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-004493 · doc1.xml · nonDerivative · entry 3 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · M. Anne Szostak Trust Disclosed balance after: 11,796 Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 22:27 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 8,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-004493 · doc1.xml · nonDerivative · entry 2 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 584 Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 22:27 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 8,790 | $43.68 | $383,947.20 |
DisclosureSEC source: 0001567619-20-004493 · doc1.xml · nonDerivative · entry 1 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,734 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2019 Filed Nov 5, 2019 23:05 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 983 | $279.99 | $275,225.35 |
DisclosureSEC source: 0001567619-19-020466 · doc1.xml · nonDerivative · entry 2 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · M. Anne Szostak Trust Disclosed balance after: 2,916 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $279.58 to a high of $280.48 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 04, 2019 Filed Nov 5, 2019 23:05 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,300 | $279.10 | $641,936.90 |
DisclosureSEC source: 0001567619-19-020466 · doc1.xml · nonDerivative · entry 1 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · M. Anne Szostak Trust Disclosed balance after: 3,899 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $278.56 to a high of $279.51 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 21:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-016170 · doc1.xml · nonDerivative · entry 3 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · M. Anne Szostak Trust Disclosed balance after: 6,199 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.